Remedy used to treat type 2 diabetes and also against obesity is manufactured by Eli Lilly
The pharmacist announced that Mounjaro, an injectable medicine used to treat type 2 diabetes and obesity, should be available in pharmacies in Brazil from June 7.
The drug is suitable for adults and is not recommended for children under 18. In Brazil, its use for weight control is still in the evaluation phase, although it is already approved for this purpose in other countries, such as the United States.
A (National Health Surveillance Agency) Mounjaro for the treatment of type 2 diabetes in September 2023.
The final price has not yet been confirmed, but according to data from (drug market regulation), the PMC (maximum price to consumer) can range from R $ 1,523.06 to R $ 4,067.81 depending on the dosage, dosage and ICMS tax rate (Tax on Circulation of Goods and Services) of each state.
The PMC, however, does not take into account other pricing adjustments, and therefore the final price paid by the consumer is not necessarily.
In recent years, remedies such as Ozepic, Saxenda and Mounjaro have become popular for use “off label”, That is, when there is a different use from the one prescribed in the leaflet, and have been used by people who want to lose weight.
In Brazilian politics, Mounjaro has become a frequent drug. Deputies (PP-AL) and (Brazil-BA Union) and Senator (PSD-AM) made use of the drug. Eduardo Cunha, former mayor, with Mounjaro.
The active ingredient of Mounjaro is tirzepatida, a substance that, like semaglutide (present in medicines also used for weight loss, such as Ozempic and Wegovy), acts on hormones related to satiety and glycemic control.
However, while semaglutado acts only on GLP-1, tirzepatida has a double effect as it also stimulates the GIP (gastric inhibitor), making its impact more potent.
Mounjaro application is done subcutaneously once a week, with a gradual increase in dosage. Possible side effects include episodes of hypoglycemia, nausea and gastrointestinal discomfort. Read the drug (PDF – 335 kb).
According to Anvisa, diabetes is a global health problem that affects approximately 463 million adults (20 to 79 years old) worldwide. Type 2 diabetes is a major cause of kidney failure, blindness, amputation and cardiovascular disease, and these complications are the main causes of death in most countries.
It is expected that the worldwide prevalence of diabetes will increase over time: in 2030, this projection is 578.4 million adults aged 20 to 79 years and, in 2045, it rises to 700.2 million.
Read more:
